Jasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note issued to investors on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $65.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 185.46% from the stock’s previous close.

Several other analysts have also recently commented on the company. TD Cowen started coverage on Jasper Therapeutics in a report on Monday, March 18th. They issued an “outperform” rating for the company. Royal Bank of Canada started coverage on Jasper Therapeutics in a report on Thursday, March 28th. They issued an “outperform” rating and a $70.00 price target for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $80.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, March 7th. Finally, Evercore ISI started coverage on Jasper Therapeutics in a research note on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price objective for the company. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Buy” and an average target price of $64.29.

Jasper Therapeutics Price Performance

JSPR opened at $22.77 on Monday. The business has a 50 day simple moving average of $25.49 and a 200-day simple moving average of $15.04. The stock has a market capitalization of $342.92 million, a P/E ratio of -3.67 and a beta of 2.25. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Monday, March 4th. The company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.65) by $0.15. Research analysts anticipate that Jasper Therapeutics will post -5 EPS for the current year.

Insider Activity at Jasper Therapeutics

In related news, major shareholder Velan Capital Investment Manag purchased 350,000 shares of the company’s stock in a transaction on Thursday, February 8th. The stock was bought at an average price of $12.95 per share, with a total value of $4,532,500.00. Following the completion of the transaction, the insider now owns 1,188,500 shares of the company’s stock, valued at approximately $15,391,075. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jasper Therapeutics

Several hedge funds have recently bought and sold shares of JSPR. Opaleye Management Inc. purchased a new position in Jasper Therapeutics during the fourth quarter worth $3,144,000. Kingdon Capital Management L.L.C. increased its position in Jasper Therapeutics by 16.4% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after buying an additional 500,000 shares in the last quarter. Monaco Asset Management SAM purchased a new position in Jasper Therapeutics during the fourth quarter worth $197,000. Cowen AND Company LLC purchased a new position in Jasper Therapeutics during the third quarter worth $140,000. Finally, Summit Trail Advisors LLC purchased a new stake in shares of Jasper Therapeutics in the third quarter valued at $46,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.